← All trials
NCT01361191
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 1, 2007
- Primary completion
- Sep 1, 2012
- Completion date
- Sep 1, 2012
- First posted
- —
- Last posted
- —
- Enrollment
- 71
- Arms / groups
- 1 / —
- Source
- AACT · pre-existing
Sponsors
- Grupo Español de Linfomas y Transplante Autólogo de Médula ÓseaLead sponsor
- Hospital Universitari Son DuretaOverall official - principal investigator
- Jerez HospitalOverall official - principal investigator
- Morales i Meseguer HospitalOverall official - principal investigator
- Duran i Reynals HospitalOverall official - principal investigator
- Son Llatzer HospitalOverall official - principal investigator
- Jaen HospitalOverall official - principal investigator
- Segovia HospitalOverall official - principal investigator
- Virgen de la Concha HospitalOverall official - principal investigator
- León HospitalOverall official - principal investigator
- University of CantabriaOverall official - principal investigator
- Hospital Clinico Lozano BlesaOverall official - principal investigator
- Clinica Universidad de NavarraOverall official - principal investigator
- Universidad Autonoma de MadridOverall official - principal investigator
- Universidad Complutense de MadridOverall official - principal investigator
- University of Las Palmas de Gran CanariaOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.